Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Amathus Therapeutics

Request full access

Advancing treatment options for Parkinson’s and Polycystic Kidney Disease through targeted therapeutic development

Cambridge, United StatesFounded 2016Biotech & Life Sciences

About Amathus Therapeutics

Amathus Therapeutics, established in 2016, is a biopharmaceutical firm concentrated on developing treatments for neurodegenerative and renal diseases. The company's scientific foundation is built upon discoveries licensed from the Icahn School of Medicine at Mount Sinai, specifically from the laboratory of Professor Yiannis A. Ioannou. Initially founded and funded by Sanofi Ventures, the corporate venture capital arm of Sanofi, and the Dementia Discovery Fund, Amathus has secured its financial footing to pursue its research objectives.

The company's core business revolves around its proprietary drug discovery platform, which develops small-molecule therapeutics designed to modulate organelle-specific chaperones. This approach targets the body's cellular stress response pathways to rescue key cellular functions associated with genetically defined diseases. The primary focus is on conditions such as Parkinson's Disease, particularly related to the PINK1 gene, and Autosomal Dominant Polycystic Kidney Disease (ADPKD). Amathus' strategy involves identifying and advancing these novel chaperone activators through the preclinical discovery phase.

A significant milestone in the company's history was the establishment of a strategic collaboration with Merck in March 2021. This partnership provides Amathus with an upfront payment and leverages Merck's extensive resources for later-stage development. The terms of the agreement grant Merck an exclusive option to acquire Amathus and its entire pipeline of mitochondrial-targeted candidates. Should Merck exercise this option, Amathus is eligible for milestone payments potentially exceeding $500 million for each successful program, with Merck assuming full responsibility for clinical development and commercialization. This business model allows Amathus to focus on its expertise in early-stage discovery while providing a clear path to market through a major pharmaceutical partner.

Source: Dealroom company data

At a glance

Founded
2016
Headquarters
Cambridge, United States
Sector
Biotech & Life Sciences

Amathus Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Amathus Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • SV Health Investors
  • Sanofi Ventures
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Amathus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Amathus Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.